BioSpace News Archive

Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the Company held a Type A meeting with the U.S. Food and Drug Administration (FDA) on June 27, 2022 regarding the path forward for the resubmission and potential approval of the New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum.

Eliassen Group, a strategic consulting company, announced today the appointment of individuals to several crucial roles: Eleanore Doyle as President, Global Head of Life Sciences and Doug Nelson as Chief Financial Officer.

Soligenix, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 2a clinical trial.

PureTech Health plc, a clinical-stage biotherapeutics company noted that its Founded Entity, Vedanta Biosciences, Inc., announced the opening of a new facility designed to manufacture clinical and commercial supply for its therapeutic portfolio, including for the planned Phase 3 study and potential commercial launch of its lead candidate, VE303, in Clostridioides difficile infection.

The OncoSignature ® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2 targeted oncology agent for solid cancers.

BrainsWay Ltd. announced that, for the first time, the Israeli Ministry of Health has approved coverage applicable to its Deep TMS™ system for the treatment of depression.

Sobi® North America announced the launch of the INTO-HLH Registry, a new disease registry for patients with hemophagocytic lymphohistiocytosis.

Panbela Therapeutics, Inc today announced the publication of preclinical data from studies of SBP-101 that demonstrated a 42% increase in median survival in a mouse model of VDID8+ ovarian cancer.

Patient procedures performed at HCA Florida Kendall Hospital and The Women’s Hospital at Jackson Memorial with first and only FDA-authorized surgical robot with humanoid-shaped arms.

Collagen Matrix, Inc., a leader in regenerative medicine, global manufacturer of collagen and other biomaterial-based medical devices, and Linden Capital Partners portfolio company (“Collagen Matrix” or “the Company”), announced today its 510(k) Clearance for a new Fibrillar Collagen Wound Dressing.